title: [Insulin treatment in children].
abstract: Improving the diabetes metabolic regulation decreases the risk of microvascular diabetic complications. Insulin treatment in children therefore tends to be intensified to multiple-dose insulin (MDI) or continuous subcutaneous insulin injection (CSII). Further, insulin analogues are increasingly used. The pharmacokinetics of human and analogue insulin are summarised. It is concluded that pharmacokinetic studies on analogue insulin in children are required. Yet, no clear evidence of improved glycaemic control of the intensified treatment regimes has been shown in children. Long-term randomised studies are needed.
authors.affiliation: Børneafdelingen, Arhus Universitetshospital, Skejby, DK-8200 Arhus N. nielbirk@rm.dk
authors.forename: Niels H
authors.initials: NH
authors.lastname: Birkebaek
authors.forename: Birgitte
authors.initials: B
authors.lastname: Hertz
authors.forename: Birthe S
authors.initials: BS
authors.lastname: Olsen
mesh_terms: D000293:Adolescent; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007332:Insulin Infusion Systems; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000493:pharmacokinetics; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D007336:Insulin, Isophane